Camargo Taps PhDs, Postdoctoral Researchers for Training
Camargo Pharmaceutical Services has tapped academic organizations close to its Raleigh, NC site in a unique internship program...
Camargo Pharmaceutical Services, which specializes in 505(b)(2) approval pathway drug development, has tapped academic organizations close to its Raleigh, NC site in a unique internship program. According to Duke University's postdoctoral services office, which is one university partnering with Camargo on this program, historically, PhD students and postdoctoral researchers were training for tenured faculty positions, but now only 20% of graduates with a PhD will go on to tenured academic appointments. With the decrease in academic appointments, more graduates with a PhD are looking for positions beyond academia and that includes positions in pharmaceutical research.
Read the full release here.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
